By utilizing a comprehensive competitive intelligence framework, Roots Analysis decoded the global GLP-1
ecosystem to deliver evidence-driven guidance for differentiation and commercial viability.
Holistic Pipeline Monitoring: We developed a structured view of all GLP-1 therapeutics
across the drug development continuum, from preclinical through marketed assets, profiling each
candidate by mechanism of action, receptor agonism profile, modality type, route of administration,
dosing regimen and clinical efficacy benchmarks. This end-to-end pipeline visibility enabled the client
to contextualize its proprietary asset against established standards and emerging next-generation
therapies, refine target product profiles and identify white-space opportunities while avoiding direct
competition with better-positioned programs.
Success Protocol Analysis: We analyzed marketed GLP-1 drugs to identify the most
critical success factors underpinning their market adoption, then systematically assessed the top six
approved products (from big pharma giants) against these parameters to quantify their relative
commercial impact. This success‑protocol framework enabled the client to internalize proven design,
clinical and go-to-market levers, informing dose optimization, line-of-therapy positioning and
competitive differentiation strategies for its development program.
Commercial & Investment Modeling: Based on clinical trial data, insights from key
opinion leaders and informed assumptions, we developed a robust methodology to estimate the global GLP-1
market size and opportunity till 2035 across conservative, base and optimistic scenarios. This also
included sales forecasts for marketed and late‑stage assets, peak‑sales potential, patent expiry timing
and detailed pricing and reimbursement assessment. This integrated commercial framework equipped the
client to quantify shareholder value creation, support internal portfolio decisions and establish a
credible investment narrative for upcoming Series B discussions.
